Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04618263 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers
A Phase 1 study, sponsored by Syndeio Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04618263 is a Phase 1 study that was terminated before completion, run by Syndeio Biosciences. The registered enrollment target is 18 participants.
The verdict
NCT04618263, a Phase 1 study, was terminated before completion, sponsored by Syndeio Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GATE-101 in normal human volunteers
Interventions
- DRUG GATE-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2021-08-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04618263
The ClinicalTrials.gov registry entry for NCT04618263 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndeio Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GATE-101 is the first listed.
NCT04618263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04618263 about?
NCT04618263 is a clinical study titled "Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers". To evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GATE-101 in normal human volunteers
What is the current status of trial NCT04618263?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-10-26. Estimated completion is 2021-08-13.
What interventions are being tested in trial NCT04618263?
The interventions under investigation include: GATE-101 (DRUG).
Who is sponsoring clinical trial NCT04618263?
This trial is sponsored by Syndeio Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.